The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Issues
Latest issue
Regular issues
Supplements
PCR Trials
All issues
Articles
Regular articles
Ahead of print
All articles
Topics
Coronary interventions
STEMI
NSTEMI
Stable CAD
Stents and scaffolds
Left main and multivessel disease
Bifurcation lesions
CTO
Other coronary interventions
Interventions for valvular disease
TAVI
Mitral valve replacement and repair
Tricuspid / Pulmonary valve
Other valvular and structural interventions
Interventions for heart failure
Acute heart failure
Chronic heart failure
Peripheral interventions
Below the knee
Abdominal aortic aneurysm
Iliac / Femoral / Popliteal
Other peripheral interventions
Interventions for hypertension
Renal artery angioplasty
Renal denervation
Other hypertension
Interventions for stroke
Carotid stenting
LAA closure
Ischaemic stroke
Other stroke interventions
News
Services
Subscribe
Advertise
Reprint-Eprint
Join our mailing list
About
Overview
Editorial board
Rights & permissions
Contact us
Author centre
Pieter Smits
Showing 1-20 of 25 articles
Comparative stent trials, a never-ending story
Smits P
June 3, 2022 | 10.4244/EIJ-E-22-00012
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial
de Winter R,
Zaman A,
Hara H,
Gao C,
Ono M,
Garg S,
Smits P,
Tonino P,
Hofma S,
Moreno R,
Choudhury A,
Petrov I,
Cequier A,
Colombo A,
Kaul U,
Onuma Y,
Serruys P
March 15, 2022 | 10.4244/EIJ-D-21-00766
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial
Smits P,
Chang C,
Chevalier B,
West N,
Gori T,
Barbato E,
Tarantini G,
Kocka V,
Achenbach S,
Dudek D,
Escaned J,
Wlodarczak A,
Abdel-Wahab M,
Esposito G,
Tijssen J,
Morice M,
Onuma Y,
van Geuns R
October 23, 2020 | 10.4244/EIJ-D-19-01079
Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial
Smits P,
Laforgia P,
Abdel-Wahab M,
Neumann F,
Richardt G,
Boxma-de Klerk B,
Lunde K,
Schotborgh C,
Piroth Z,
Horak D,
Wlodarczak A,
Frederix G,
Omerovic E
June 25, 2020 | 10.4244/EIJ-D-20-00012
The obesity paradox revisited: body mass index and long-term outcomes after PCI from a large pooled patient-level database
Wolny R,
Maehara A,
Liu Y,
Zhang Z,
Mintz G,
Redfors B,
Madhavan M,
Smits P,
von Birgelen C,
Serruys P,
Mehran R,
Leon M,
Stone G
January 17, 2020 | 10.4244/EIJ-D-19-00467
Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention
Brener S,
Leon M,
Serruys P,
Smits P,
von Birgelen C,
Mehran R,
Kirtane A,
Witzenbichler B,
Rinaldi M,
Metzger C,
Mazzaferri E,
Zhang Z,
Stone G
August 9, 2019 | 10.4244/EIJ-D-19-00262
Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy
Asano T,
Katagiri Y,
Collet C,
Tenekecioglu E,
Miyazaki Y,
Sotomi Y,
Amoroso G,
Aminian A,
Brugaletta S,
Vrolix M,
Hernández-Antolín R,
van de Harst P,
Iñiguez A,
Janssens L,
Smits P,
Wykrzykowska J,
Ribeiro V,
Pereira H,
da Silva P,
Piek J,
Reiber J,
von Birgelen C,
Sabaté M,
Onuma Y,
Serruys P
August 3, 2018 | 10.4244/EIJ-D-17-00461
A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial
Paradies V,
Ben-Yehuda O,
Jonas M,
Banai S,
Iñiguez A,
Perlman G,
Kandzari D,
Stone G,
Smits P
May 20, 2018 | 10.4244/EIJ-D-17-00890
First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial
von Birgelen C,
Asano T,
Amoroso G,
Aminian A,
Brugaletta S,
Vrolix M,
Hernández-Antolín R,
van de Harst P,
Iñiguez A,
Janssens L,
Smits P,
Wykrzykowska J,
Ribeiro V,
Pereira H,
da Silva P,
Piek J,
Onuma Y,
Serruys P,
Sabaté M
April 20, 2018 | 10.4244/EIJ-D-17-00462
Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions
Fam J,
Ojeda S,
Garbo R,
Latib A,
La Manna A,
Vaquerizo B,
Boukhris M,
Vlachojannis G,
van Geuns R,
Ezhumalai B,
Kawamoto H,
van der Sijde J,
Felix C,
Pan M,
Serdoz R,
Boccuzzi G,
De Paolis M,
Sardella G,
Mancone M,
Tamburino C,
Smits P,
Di Mario C,
Seth A,
Serra A,
Colombo A,
Serruys P,
Galassi A,
Zijlstra F,
Van Mieghem N,
Diletti R
June 20, 2017 | 10.4244/EIJ-D-16-00253
Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months
Felix C,
Vlachojannis G,
IJsselmuiden A,
Fam J,
Smits P,
Lansink W,
Diletti R,
Zijlstra F,
Regar E,
Boersma E,
Onuma Y,
van Geuns R
June 2, 2017 | 10.4244/EIJ-D-17-00119
Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials
Vlachojannis G,
Puricel S,
Natsuaki M,
Morimoto T,
Smits P,
Kimura T
March 20, 2017 | 10.4244/EIJ-D-16-00773
Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial
Chevalier B,
Onuma Y,
Van Boven A,
Piek J,
Sabaté M,
Helqvist S,
Baumbach A,
Smits P,
Kumar R,
Wasungu L,
Serruys P
October 20, 2016 | 10.4244/EIJY16M08_01
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial
Vlachojannis G,
Smits P,
Hofma S,
Togni M,
Vázquez N,
Valdes M,
Voudris V,
Puricel S,
Slagboom T,
Goy J-J,
den Heijer P,
van der Ent M
July 20, 2015 | 10.4244/EIJV11I3A53
Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial
Hofma S,
Smits P,
Brouwer J,
Velders M,
van't Hof A,
Quere M,
de Vries C,
Van Boven A
March 20, 2015 | 10.4244/EIJY15M01_03
Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)
Simsek C,
Magro M,
Onuma Y,
Boersma E,
Smits P,
Dorange C,
Veldhof S,
Regar E,
Serruys P,
van Geuns R
June 20, 2014 | 10.4244/EIJV10I2A38
Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months
Serruys P,
Onuma Y,
Garcia-Garcia H,
Muramatsu T,
van Geuns R,
De Bruyne B,
Dudek D,
Thuesen L,
Smits P,
Chevalier B,
McClean D,
Koolen J,
Windecker S,
Whitbourn R,
Meredith I,
Dorange C,
Veldhof S,
Hebert K,
Rapoza R,
Ormiston J
March 20, 2014 | 10.4244/EIJV9I11A217
STEMI patients and non-culprit lesions: what to do and when?
Smits P
December 27, 2013 | 10.4244/EIJV9I8A150
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials
Gogas B,
Bourantas C,
Garcia-Garcia H,
Onuma Y,
Muramatsu T,
Farooq V,
Diletti R,
van Geuns R,
De Bruyne B,
Chevalier B,
Thuesen L,
Smits P,
Dudek D,
Koolen J,
Windecker S,
Whitbourn R,
McClean D,
Dorange C,
Miquel-Hebert K,
Veldhof S,
Rapoza R,
Ormiston J,
Serruys P
October 25, 2013 | 10.4244/EIJV9I6A115
A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients
Vranckx P,
Verheugt F,
de Maat MP,
Ulmans V,
Regar E,
Smits P,
ten Berg J,
Lindeboom W,
Jones R,
Friedman J,
Reilly P,
Leebeek F
January 18, 2013 | 10.4244/EIJV8I9A162
1
2
Latest news
NEW ISSUE
A TAVI in Bicuspid Anatomies; TMVI; Bailout-TEER or Medical Therapy; DRT following LAAO; Cost-Effectiveness of FFR-Guided MVD Revascularisation in STEMI and more
June 24, 2022
AHEAD OF PRINT
Bioprosthetic dysfunction of the LOTUS valve
FREE ARTICLE - Rutger-Jan Nuis et al
June 17, 2022
AHEAD OF PRINT
Coronary access after ViV-TAVI with ACURATE neo2
FREE ARTICLE - Arif A. Khokhar et al.
June 16, 2022
AHEAD OF PRINT
Prognostic value of structural and functional microvascular dysfunction
FREE ARTICLE - Coen K.M. Boerhout et al
June 13, 2022
AHEAD OF PRINT
TAVR with the ACURATE neo2
FREE ARTICLE - Andrea Scotti et al
June 8, 2022
AHEAD OF PRINT
Antithrombotic strategy selection using smartphone technology
FREE ARTICLE - Jaya Chandrasekhar et al
June 3, 2022
AHEAD OF PRINT
The fingerprints of plaque rupture healing as detected by serial OCT imaging
FREE ARTICLE - Rocco Vergallo et al
June 2, 2022
Coronary
Valvular disease
Heart failure
Peripheral
Hypertension
Stroke